Löschung

Abbott to donate HIV tests, cut drug prices in Africa

Reuters NewMedia - June 19, 2002


--------------------------------------------------
CHICAGO, June 19 (Reuters) - Health care products maker Abbott Laboratories Inc. said on Wednesday it will donate up to 20 million HIV tests, mainly in Africa -- where the disease kills more than 5,000 die every day -- to help prevent babies from contracting the deadly virus from their mothers.
In addition, Abbott said it is cutting the price of its anti-HIV drugs sold in African and least developed countries to about $500 a year per patient from the current $650 a year. The drugs are currently sold at cost in those areas.

The program was announced on the same day that President George W. Bush pledged $500 million to help fight the spread of AIDS in Africa and the Carribean. The president's plan is aimed at reducing mother-to-child infection transference.

An estimated 40 million people worldwide have HIV or AIDS, most of them in sub-Saharan Africa, where more than 5,000 Africans die each day.

Abbott said the HIV rapid tests would be donated over five years in African countries and other less developed nations, to programs aimed at preventing mother-to-child transmission of the disease. Abbott currently sells the tests at cost, about 80 cents each.

Sonst gehts dir aber gut, oder ;)

Muahahahahahahhahahahahaa

was sie schon immer gut konnten,dilution oder Verwässerung des Aktienwertes nennt man sowas
26,666,666  shares  of  common  stock  that may be  issued  upon the
           conversion  by the selling  security  holders of  $8,000,000  of our
           Secured 8%  Convertible  Promissory  Notes at a conversion  price of
           $0.30 per share; and

     o     26,666,666  shares of common stock underlying  Series A common stock
           purchase warrants exercisable beginning six months after issuance at
           an exercise price of $0.325 per share issued to the selling security
           holders concurrently with the 8% Notes; and

     o     12,000,000  shares of common stock underlying  Series B common stock
           purchase warrants exercisable beginning six months after issuance at
           an exercise price of $0.325 per share issued to the selling security
           holders concurrently with the 8% Notes; and.....
.............
xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3560092

finance.lycos.com/qc/stocks/quotes.aspx?symbols=AMEX:HIV
aber Gefahr droht:This issue is currently below the continued listing standards of the Amex, which can be viewed in the Amex Company Guide

P/E ratio -2.00  Short Interest 209,230 !!!!
Earnings Per Share 0.00  Current yield N.A.
Shares Outstanding 171,243,000  Dividend Info
Market Cap 34,248,600    

<!--StartFragment -->Konnte deine Angabe unter obigem Link nicht finden. Wo steht das bitte?

In USA kann man normalerweise keine Pennystocks shorten  und Optionen gibt es auch nicht

<!--StartFragment -->

CALYPTE BIOMEDICAL - American Stock Exchange: HIV

Options for: Show All

Calls

Puts

Symbol

Bid

Ask

Last

Chg

Vol

Open Int

Strike

Exp Date

Symbol

Bid

Ask

Last

Chg

Vol

Open Int

None found.

 

HIV - Calypte Biomedical Corp (AMEX)

7/22/2005

 

Danke für Antwort

gs

<!--StartFragment --> Shares short 0.19 

 Short interest ratio 0.33 

 Percentage of float 0.17

Somit nicht praktikabel, wenn ich das richtig interpretiere.

 

gruß

gs

HIV schliesslich sind sie noch an der Amex gelistet als Pennywert,seit Jahren  ohne Einnahmen und werden somit bald rausfliegen
aber man könnte sicher auch Pennywerte vom OTC shorten über die Marketmaker als naked shorting

ich würde bei caly aber eher beobachten und leerkaufen ;-)
die haben nach wie vor potenzial. amex hin oder her... das hat caly ja eh nie richtig was gebracht!!

Interesse gefunden.

Selbst wenn es Eines gibt, so wird es keine Möglichkeit gibt sie zu shorten.

Bei den Amerikanern ist ein Wert unter 5 $ ein Pennystock und wird weder beliehen noch gibt es dafür Optionen, noch Leerverkäufe.

Dass Makler leerverkaufen, auch an der OTC, da bin ich mir ziemlich sicher, ob die das allerdings legal machen, wage ich zu bezweifeln.

Habe einen amerik. Broker, bei dem ich alles leerverkaufen kann, was ich nicht im Depot habe. den frage ich mal zu dem Thema.
Jedenfalls besteht kein short Interesse bei dem Wert im Gegensatz zu ELK z,B. habe ich folgende Zahlen bekommen:

Short interest As published monthly by the exchanges. Based on most recent settlement date.   Current   1 month change
Shares short        0.77 30.63%
Short interest ratio 2.69 43.85%
Percentage of float 4.31 30.62%

noch interssanter bei GOOG:

Short interest As published monthly by the exchanges. Based on most recent settlement date.   Current   1 month change
Shares short 9.55        -0.93%
Short interest ratio 0.55 -30.31%
Percentage of float 5.30 -0.93%

Hier sind es fast 10 % die derzeit short sind ohne die Puts zu zählen.



gruß
geldschneider

www.amex.com/   oben HIV eingeben und dann auf den Wert klicken,dann geht links eine Tabelle auf mit Fundamentals ,da klickste drauf und siehst den short interest ,ist zwar gering aber er steht da

nicht aber dass sie geshortet werden. Und diesen Wert von Amex kann man getrost vergessen,

habe mal einen grö0eren Wert im vErgleich gesucht, hier wäre das Short Interesse unter Amex das 5 fache des tgl. Handelsvolumen!

<!--StartFragment --> 

GRU - Gurunet Corp (AMEX)

7/22/2005

Der Chart zeigt aber klar an, dass zum shorten kein aktueller Bedarf ist. Möglicherweise sammelt die AMEX alle Anfragen. Die echten Zahlen sehen so aus:

<!--StartFragment --> Short interest Current 1 month change Shares short 0.96 2.45% Short interest ratio 2.30 33.92% Percentage of float 14.77 2.46%

Nach Amex wäre short interesset in ganzen Zahlen:

<!--StartFragment -->

Last Sale Net Change % Change Volume Last Updated $15.23 0.46 3.11 216,100 07/22/05 4:22 PM ET

< script language=javascript>     function openDividendSearch()     {          window.open('/amextrader/?href=/amextrader/dailylist/search.jsp?pop_searchby=dividends&pop_fromdate=01/24/2005&pop_todate=07/24/2005&pop_eventtype=0&pop_searchtext=GRU','dividendSearch');     }     < /script>

P/E ratio	-8.00		Short Interest	980,597
Earnings Per Share	-2.00		Current yield	N.A.
Shares Outstanding	6,945,000		Dividend Info
Market Cap	105,772,350

Nicht so leicht durchschaubar, nicht wahr.

gruß

geldschneider

besoffen....

feiern und tröstet mir den broker. sagt ihm, er soll es nicht so schwer nehemen:

mal verliert man, mal gewinnen die anderen.

in diesem sinne schönen tag noch mein lieber nicht lernfähiger gindants

.

also ich selber oute mich, dass ich damals vor langer zeit caly mal als schnellschuß gekauft habe, sogar mehrfach, bis mir ein gewisser user "neono" aus W:O mal ganz deutlich und brutal die wahrheit erzählt hat. das hatte gesessen. somit bin ich damals vor dem splitt zu 0,092€ rausgegangen, was jetzt über 2,70$ wären. davon könnt ihr jetzt nur träumen. von daher weiß ich, wie schnell man gerade am anfang auf die tollen kommentare und fiktionen, die einem hier von euch als fakten verkauft werden, reinfallen kann.

3) natürlich bringt euch das einsteigen neuer etwas, die euch dann nämlich noch euren wertlosen schrott abkaufen...und zwar völlig überteuert.


ich wette: 90% von euch hardcorern sind nicht so beschränkt, als dass sie nicht schon lange wissen, dass caly ein finanzielles massengrab ist!!!
man hält nur noch offiziell die fahne hoch, um

a) sich nicht öffentlich eingestehen zu müssen, dass man sich förmlich über jahre auf dem holzweg festgekettet hat. das eingeständnis tut einfach zu weh, der gesichtsverlust wäre zu groß!!! dabei ist das kindliche festhalten (nein caly ist klasse und wird der renner, wartet ab, bald stehen wir auf 1$...) je länger es durchgezogen wird noch lächerlicher und unglaubwürdiger, als ein eingestehen des fehlers, bei dem sicherlich einige den hut vor euch ziehen würden!

b) bei einem öffentlichen eingestehen des fehlers, gehen selbst die letzten "jünger" und "glaubenstreuen" (offen gesagt: beschränkten) panikartig laufen. es wäre dann keiner mehr da, der euch noch zu einem schmerzvollen, aber dennoch notgedrungenen akzeptablen, preis die aktien abkauft. dann könnt ihr nämlich nicht mehr irgendwann "vollzug" melden, so nach dem motto: " auch ich habe es jetzt endlich eingesehen, habe es verstanden und bin noch soeben zum preis von 0,0xx$ raus.


das mein lieber broker ist nämlich das, was in den fettinvestierten vorgeht. zur not halt eben die verluste auf kosten anderer verringern.

nur: mit der masche kommt ihr hier nicht durch!!!

Calypte Biomedical Announces Second Quarter and Six-Month Financial Results
LAKE OSWEGO, Ore., Aug. 15 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced financial results for the second quarter and six-months ended June 30, 2005. Revenue for the quarter totaled $794,000 compared with $910,000 for the comparable period in 2004. The net loss for the quarter was approximately $1.72 million, or $.01 per common share, compared to a net loss of $3.24 million or $.02 for the three months ended June 30, 2004. The net loss for the second quarter of 2005 included net non-cash income of approximately $2.2 million and the net loss for the second quarter of 2004 included approximately $0.5 million in non-cash charges.

The decrease in revenue for the quarter is primarily attributable to transitional and timing issues related to the lab-based HIV-1 legacy products. Sales of the BED Incidence Test grew by over 100% on a sequential quarterly basis. This product was released at the end of the third quarter of 2004.

For the six-month period ended June 30, 2005, revenues totaled $1.46 million versus revenues of $1.88 million for the same period in 2004. The net loss was $5.03 million or $.03 per common share for the six-months ended June 30, 2005, compared to a net loss of $7.29 million or $0.05 per share. The net loss for the six-months ended June 30, 2005 included net non- cash income of approximately $1.8 million and the net loss for the six months ended June 30, 2004 included approximately $1.0 million in non-cash charges.

The non-cash income for the current quarter and year-to-date were primarily related to non-cash interest income resulting from the accounting for Calypte's recent financing instruments, whereas the non-cash charges in the previous year included expense attributable to grants of common stock, options, and warrants as compensation for services plus expense related to the accounting for the Company's then-outstanding financing instruments.

Dr Richard George, President and Chief Executive Officer of Calypte, said, "In the time since we last updated investors, our path forward in the China market has crystallized significantly. We have also been expanding our international distribution channels, forging ahead with regulatory trials for Aware(TM) products, and enjoying significant success with the BED Incidence test, both domestically and abroad. We look forward to sharing this information with our investors during the conference call."

Calypte management will host a conference call at 4:30 pm Eastern Time today to discuss and answer questions regarding the Company's second quarter financial results as well as provide an update on the Company's current activities.

The call can be accessed in the U.S. by dialing 1-800-884-5695 and outside of the U.S. 1-617-786-2960 and entering conference identification number 37738824. An audio replay will be available at http://www.calypte.com until September 19, 2005.

About Calypte Biomedical:

Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.


              CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

                   CONSOLIDATED STATEMENTS OF OPERATIONS
                   (in thousands, except per share data)
                                 Unaudited


                              Three Months Ended         Six Months Ended
                                    June 30,                 June 30,
                               2005         2004         2005         2004

   Revenues:
    Product sales            $  794     $    910    $   1,459    $   1,881
    Other                         -            -            -            -
     Total revenues             794          910        1,459        1,881

    Cost of product sales     1,766        1,013        3,286        2,993
     Gross Margin (Loss)
      on product sales         (972)        (103)      (1,827)      (1,112)

   Other operating expenses:
    Research and development
     costs                      710          573        1,472        1,114
    Selling, general and
     administrative costs     2,046        2,349        3,460        4,546

     Total other operating
      expenses                2,756        2,922        4,932        5,660

       Loss from operations  (3,728)      (3,025)      (6,759)      (6,772)

   Interest and other income
    (expense) (primarily
    non-cash for all
    periods)                  2,013         (219)       1,727         (511)


       Loss before income
        taxes                (1,715)      (3,244)      (5,032)      (7,283)

   Income taxes                  (2)           -           (2)          (2)


   Net loss attributable
    to common stockholders $ (1,717)    $ (3,244)   $  (5,034)   $  (7,285)

   Net loss per share
    attributable to common
    stockholders
     (basic and diluted)   $  (0.01)    $  (0.02)   $   (0.03)   $   (0.05)

   Weighted average shares
    used to compute net loss
    per share attributable
    to common stockholders
     (basic and diluted)    171,473      148,282      171,288      142,481


               CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARY

                      CONSOLIDATED BALANCE SHEET DATA
                               (in thousands)
                                 Unaudited

                                                  June 30,     December 31,
                                                    2005           2004



   Cash and cash equivalents                     $  2,096       $  1,075
   Working capital                                 (1,933)        (4,772)
   Total Assets                                     8,644          7,930
   Convertible debentures, net of discount
    - current portion                                  52             37
   Anti-dilution obligation                             -          1,638
   Convertible notes, net of discount
    -  non-current portion                          1,113              -
   Note derivative liability                        3,232              -
   Other long term liabilities                        234            357
   Mandatorily redeemable Series A preferred stock  2,876          2,816
   Total stockholders' deficit                     (3,998)        (3,293)


    Company Contact:                  Investor Relations Contact:
    Richard Brounstein, EVP & CFO     Tim Clemensen,
    (971) 204-0282                    Rubenstein Investor Relations
    Email: rbrounstein@calypte.com    Phone: (212) 843-9337
                                      Email: tclemensen@rubensteinir.com

SOURCE  Calypte Biomedical Corporation
   -0-                             08/15/2005
   /CONTACT:  Richard Brounstein, EVP & CFO, Calypte Biomedical Corporation,
+1-971-204-0282, rbrounstein@calypte.com; Tim Clemensen, Rubenstein Investor
Relations, +1-212-843-9337, tclemensen@rubensteinir.com/
   /Web site:  http://www.calypte.com /
   (HIV)

CO:  Calypte Biomedical Corporation
ST:  Oregon
IN:  HEA MTC BIO
SU:  ERN CCA

WS
-- NYM142 --
2164 08/15/2005 09:48 EDT http://www.prnewswire.com







--------------------------------------------------

© 2004 Calypte Biomedical | Terms & Conditions
Contact Calypte Webmaster
Our Rockville, Maryland USA
Manufacturing Facility Quality System
is Certified as conforming to the requirements of ISO 13485:1996.

To view PDF files

bei gelegenheit erklären:

einer auf dem ich dich festnageln werde, da wirst du in neuen erklärungsnotstand geraten:

1133. @Lucky   Brokersince1994   20.08.05 20:15  



Wenn du die 11200€ verkraften kannst und nicht verdienen willst, kannst du ja einen anderen damit Glücklisch machen, der jenige wird sich freuen..

Wie gern würde Ich dieser jenige sein , muß aber biß Ende diesen Monat abwarten, vielleicht schlage Ich dann nochmal zu *g* ...

Solche Traumkurse werden wir ganz bestimmt nicht mehr sehen ...


Gruß

C.O  


wetten, dass du dich dann auch wieder rauswinden willst mit hilfe der mods? du wirst wieder sagen, du hast es nur im spaß gemeint, gelle?

Support/Resistance
Type Value Conf.
resist. 0.34 2
resist. 0.33 10
resist. 0.30 2
resist. 0.28 2
resist. 0.27 11
resist. 0.23 14
resist. 0.22 9
resist. 0.21 10
resist. 0.20 35
resist. 0.18 16
resist. 0.17 2
resist. 0.16 2
resist. 0.15 4
resist. 0.14 2